ORPHA:309854
Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome
Publications
995
Trials
0
Interventional, condition-specific
Researchers
0
Distinct authors in sample
Gene link
SLC30A10
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of manganese transport characterized by childhood onset of extrapyramidal movement disorder (including dystonia, tremor, and bradykinesia), liver cirrhosis, polycythemia, and hypermanganesemia. Cases with spastic paraparesis without extrapyramidal dysfunction have also been reported. Cognitive functions are preserved. Brain imaging findings are consistent with deposition of manganese in the basal ganglia, dentate nucleus, brain stem, and anterior pituitary.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013208
- MeSH:C548016
- OMIM:613280
- UMLS:C2750442
Additional Mondo synonyms (1)
cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — SLC30A10
- LiteraturePresent
995 matched papers (787 in last 10 years) Source
- Phenotype characterisedPresent
59 HPO annotations (e.g. Hypomimic face; Dysarthria; Hypertonia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (SLC30A10).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
59
Associated phenotypes · MONDO:0013208
- Hypomimic face
- Dysarthria
- Hypertonia
- Micronodular cirrhosis
- Splenomegaly
Showing 5 of 59 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Edetic Acid · therapeutic
Literature
Is anyone studying this?
995
995 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
995 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
787 in the last 10 years · low confidence
Phrase hits: 0 · MeSH hits: 0
Who's working on it?
0
Distinct author names in 0 sampled papers.
Who's working on it?
No author names could be extracted from the sampled publications. Try the Europe PMC query in “How we counted this,” or contact an umbrella rare-disease organisation for researcher referrals.
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN17701271·Not yet recruiting·129Xenon MRI study of the effects of Mepolizumab on inflammation in the lungs of patients with chronic obstructive pulmonary disease (COPD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34498249·Recruiting·A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3-stage metabolic dysfunction-associated steatohepatitis (BOS-580-302)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11974930·No longer recruiting·Does daily buttermilk intake improve blood lipid levels in perimenopausal women?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN88133553·Recruiting·A staged dose-finding and challenge/rechallenge study of Staphylococcus aureus nasal colonisation in healthy adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13720638·Recruiting·Safety and tolerability of APL-3007 administered as a single dose in addition to background therapy with a C5 inhibitor in adults with paroxysmal nocturnal hemoglobinuria
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12537955·Not yet recruiting·Comparing a new combination of medicines to the usual intensive chemotherapy treatment given to participants who have been recently diagnosed with acute myeloid leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13575129·Recruiting·Study to test the non-inferiority of the inactivated trivalent influenza vaccine adjuvanted with IB160 from Instituto Butantan compared to a high-dose inactivated trivalent influenza vaccine in adults aged 60 years and older
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16600368·Recruiting·Comparison of a low dose of the anticlotting drug apixaban with the standard dose of apixaban in patients with the heart rhythm disturbance known as atrial fibrillation who have undergone stenting treatment of their heart arteries and are intended to receive standard-dose apixaban along with another anticlotting drug, ticagrelor
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74827499·No longer recruiting·Can ear acupressure help people with severe liver disease sleep better?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73938525·Recruiting·A study testing a more precise type of radiotherapy for cancer to reduce pain or discomfort
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16819837·Recruiting·The use of CARBALIVE in the treatment of cholestatic liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13410885·No longer recruiting·The beneficial effect of two varieties of apples, such as Golden Delicious and Canadian White Renetta, on the improvement of normal lipid and glucose metabolism in insulin-resistant subjects with and without a diagnosis of non-alcoholic fatty liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26415952·Recruiting·A Study to evaluate novel KarX and KarT Prototypes versus the KarXT and KarX-EC reference following single doses, and to explore the effect of food after multiple doses of selected prototypes in healthy adult participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73588250·No longer recruiting·The purpose of the trial is to test the safety, tolerability and efficacy of the drug tildacerfont, that is being developed for the treatment of major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15110009·No longer recruiting·Using genetic testing to personalize heart treatment for patients undergoing stent procedures in Qatar
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49320109·Recruiting·A CAR T trial for amyloid light chain amyloidosis (AL Amyloid)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11134984·Recruiting·CLArithromycin for post-Stroke Pneumonia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91656864·No longer recruiting·RATIONALE-15: Carriage to assess the protection of new pneumococcal vaccines- PCV15
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13284643·No longer recruiting·Exploring Co-infection with Live Attenuated Influenza Vaccine and PneumococcuS in healthy oldEr adults (ECLIPSE)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18175685·No longer recruiting·Stratification of clinically vulnerable people for COVID-19 risk using antibody testing
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10203365·Recruiting·Investigating and optimising physical function with weight loss
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18116615·No longer recruiting·A study to evaluate the prevalence and distribution of steatotic and fibrotic liver disease across India
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12005942·No longer recruiting·A study to evaluate the effect of itraconazole and carbamazepine on the processing of fenebrutinib by the body in healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16638723·No longer recruiting·Severe obesity and low muscle mass and function
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46375134·No longer recruiting·Targeted use of low-dose colchicine in patients with coronary artery disease and high clinical risk
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome" OR "cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome") OR (MESH:"Hypermanganesemia with Dystonia Polycythemia and Cirrhosis") OR ("SLC30A10" OR "SLC30A10 syndrome" OR "SLC30A10-related")MeSH descriptor terms unioned into the query: Hypermanganesemia with Dystonia Polycythemia and Cirrhosis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome" OR "cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome" OR "Hypermanganesemia with Dystonia Polycythemia and Cirrhosis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: none
Parent literature probe: hypermanganesemia with dystonia (MONDO:0000214) — 142 hits
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (995) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T12:58:19.674Z
